Home>Topics>Companies>Novartis

Novartis NVS

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. UPDATE 1- Novartis digs deeper into cancer with up to $750 mln Aduro deal

      Headlines

      Mon, 30 Mar 2015

      * Novartis also picks top scientist to lead immuno-oncology (Adds details on Aduro's planned IPO, analyst comment)

    2. Novartis digs deeper into cancer with up to $750 mln Aduro deal

      Headlines

      Mon, 30 Mar 2015

      March 30 (Reuters) - Swiss drugmaker Novartis is digging deeper into the world of cancer immunotherapy - one of the hottest areas of drug research - through a tie-up with California-based Aduro...

    3. BRIEF- Novartis says to make payment of $200 mln to Aduro

      Headlines

      Mon, 30 Mar 2015

      * Says accelerates cancer immunotherapy efforts with Aduro Biotech alliance and launch of new immuno-oncology research group.

    4. GSK agrees UK deal for meningitis shot after Novartis stand-off

      Headlines

      Sun, 29 Mar 2015

      LONDON, March 29 (Reuters) - GlaxoSmithKline has reached a deal with the British government to supply a new meningitis B vaccine, following a lengthy stand-off over price with the product's previous owner Novartis .

    5. Amgen to appeal rejection of bid to block Novartis biosimilar drug

      Headlines

      Wed, 25 Mar 2015

      SAN FRANCISCO, March 25 (Reuters) - Amgen Inc will appeal the rejection of its bid to block the sale of Novartis AG 's biosimilar form of Neupogen, Amgen's blockbuster drug used to prevent infections...

    6. BRIEF-Cytos Biotechnology: Novartis buys out CAD 106 license agreement for CHF 4 mln

      Headlines

      Wed, 25 Mar 2015

      * Novartis buys out CAD 106 license agreement for 4 million Swiss francs ($4 million)

    7. UPDATE 1-Bristol, Sanofi and Novartis drugs to shine among 2015 launches

      Headlines

      Mon, 23 Mar 2015

      * Up from three potential $1 billion-plus drugs in 2014 (Updates with link to report, paragraph 5)

    8. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

      Headlines

      Mon, 23 Mar 2015

      drug manufacturer and solidified its ranking as a generics industry leader along with Teva, Sandoz (a subsidiary of Novartis NVS ), and Mylan. We estimate that these four companies have nearly 50% of the global retail generic industry market

    9. Bristol, Sanofi and Novartis drugs to shine among 2015 launches

      Headlines

      Mon, 23 Mar 2015

      LONDON, March 23 (Reuters) - Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion-plus sales potential, according to a Thomson Reuters analysis.

    10. Social Innovation: Putting a Number on Saving the World

      Headlines

      Fri, 20 Mar 2015

      was purchase/volume guarantees for vaccines and contraceptive implants. “We would go to a Merck, a Bayer, a Novartis , an Indian vaccine manufacturer and say, ‘If you provide these volumes over this time, we’ll guarantee that

    « Prev12345Next »
    Content Partners